JPMorgan views the 9% selloff in shares of Novo Nordisk (NVO) after the failure of semaglutide in Alzheimer’s as an overreaction. While the news removes a potential upside share driver, there is limited to no impact on Novo forecasts, the analyst tells investors in a research note. JPMorgan keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk shares drop 10% after Alzheimer’s drug trial misses key target
- Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club
- Mondelez price target lowered to $62 from $63 at Piper Sandler
- PepsiCo price target lowered to $161 from $162 at Piper Sandler
- Boston Beer price target lowered to $220 from $230 at Piper Sandler